Search

Your search keyword '"Below, Eduard"' showing total 10 results
Start Over Author "Below, Eduard"
10 results on '"Below, Eduard"'

1. Targeted therapy with the antibody-drug conjugate sacituzumab-govitecan as a promising treatment strategy for head and neck squamous cell carcinoma

Author

Maas, Alexander Philippe, additional, Sanders, Christine, additional, Gredig, Nina Marie, additional, Eckrich, Jonas, additional, Ernst, Benjamin, additional, Klümper, Niklas, additional, Below, Eduard, additional, Kristiansen, Glen, additional, Dietrich, Dimo, additional, and Strieth, Sebastian, additional

Published
2024
Full Text
View/download PDF

2. Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer.

Author

Weiten, Richard, Niemann, Max, Below, Eduard, Friker, Lea L., Ralser, Damian J., Toma, Marieta, Kristiansen, Glen, Hahn, Oliver, Zechel, Sabrina, Grünwald, Viktor, Bald, Tobias, Siewert, Johannes, Pietsch, Torsten, Ritter, Manuel, Hölzel, Michael, Eckstein, Markus, Alajati, Abdullah, Krausewitz, Philipp, and Klümper, Niklas

Subjects
CASTRATION-resistant prostate cancer, ANTIBODY-drug conjugates, PROSTATE cancer, IMMUNOSTAINING, PROTEIN expression, SURVIVAL rate
Abstract

Purpose: Improved survival rates have been observed in castration‐resistant prostate cancer (CRPC) due to advancements in treatment options. However, individuals with brain metastases still have limited therapeutic options and an unfavorable prognosis. Therefore, there is an urgent need to explore new therapeutic avenues, such as antibody‐drug conjugates (ADCs), which have demonstrated significant clinical activity against active brain metastases in solid tumors. Our objective was to determine the expression levels of the ADC targets Trop‐2 and NECTIN‐4 in cerebral metastasized CRPC (mCRPC). Methods: Immunohistochemical staining of Trop‐2 and NECTIN‐4 with evaluation of H‐score was performed in CRPC brain metastases (n = 31). Additionally, we examined Trop‐2 protein expression in prostate cancer cell lines and studied their responsiveness to the anti‐Trop‐2 ADC Sacituzumab govitecan (SG) in vitro. Results: Our analysis revealed that most patients exhibited moderate to strong Trop‐2 expression [n = 27/31 with H‐score ≥100, median H‐score 220 (IQR 180–280)], while NECTIN‐4 was absent in all cerebral metastases. Mechanistically, we demonstrated that the efficacy of SG depends on Trop‐2 expression levels in vitro. Overexpression of Trop‐2 in Trop‐2‐negative PC‐3 cells led to sensitization to SG, whereas CRISPR‐Cas9‐mediated knockdown of Trop‐2 in Trop‐2‐expressing DU‐145 cells conferred resistance to SG. Conclusion: The substantial expression of Trop‐2 in cerebral metastases, along with our preclinical in vitro results, supports the efficacy of SG in treating cerebral mCRPC. Thus, our results extend the understanding of the potential of ADCs in prostate cancer treatment and provide an additional treatment strategy for the challenging subset of patients with cerebral metastases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Author

Klümper, Niklas, primary, Ralser, Damian J., primary, Ellinger, Jörg, primary, Roghmann, Florian, primary, Albrecht, Julia, primary, Below, Eduard, primary, Alajati, Abdullah, primary, Sikic, Danijel, primary, Breyer, Johannes, primary, Bolenz, Christian, primary, Zengerling, Friedemann, primary, Erben, Philipp, primary, Schwamborn, Kristina, primary, Wirtz, Ralph M., primary, Horn, Thomas, primary, Nagy, Dora, primary, Toma, Marieta, primary, Kristiansen, Glen, primary, Büttner, Thomas, primary, Hahn, Oliver, primary, Grünwald, Viktor, primary, Darr, Christopher, primary, Erne, Eva, primary, Rausch, Steffen, primary, Bedke, Jens, primary, Schlack, Katrin, primary, Abbas, Mahmoud, primary, Zschäbitz, Stefanie, primary, Schwab, Constantin, primary, Mustea, Alexander, primary, Adam, Patrick, primary, Manseck, Andreas, primary, Wullich, Bernd, primary, Ritter, Manuel, primary, Hartmann, Arndt, primary, Gschwend, Jürgen, primary, Weichert, Wilko, primary, Erlmeier, Franziska, primary, Hölzel, Michael, primary, and Eckstein, Markus, primary

Published
2023
Full Text
View/download PDF

4. Data from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Author

Klümper, Niklas, primary, Ralser, Damian J., primary, Ellinger, Jörg, primary, Roghmann, Florian, primary, Albrecht, Julia, primary, Below, Eduard, primary, Alajati, Abdullah, primary, Sikic, Danijel, primary, Breyer, Johannes, primary, Bolenz, Christian, primary, Zengerling, Friedemann, primary, Erben, Philipp, primary, Schwamborn, Kristina, primary, Wirtz, Ralph M., primary, Horn, Thomas, primary, Nagy, Dora, primary, Toma, Marieta, primary, Kristiansen, Glen, primary, Büttner, Thomas, primary, Hahn, Oliver, primary, Grünwald, Viktor, primary, Darr, Christopher, primary, Erne, Eva, primary, Rausch, Steffen, primary, Bedke, Jens, primary, Schlack, Katrin, primary, Abbas, Mahmoud, primary, Zschäbitz, Stefanie, primary, Schwab, Constantin, primary, Mustea, Alexander, primary, Adam, Patrick, primary, Manseck, Andreas, primary, Wullich, Bernd, primary, Ritter, Manuel, primary, Hartmann, Arndt, primary, Gschwend, Jürgen, primary, Weichert, Wilko, primary, Erlmeier, Franziska, primary, Hölzel, Michael, primary, and Eckstein, Markus, primary

Published
2023
Full Text
View/download PDF

5. Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Author

Klümper, Niklas, primary, Ralser, Damian J., primary, Ellinger, Jörg, primary, Roghmann, Florian, primary, Albrecht, Julia, primary, Below, Eduard, primary, Alajati, Abdullah, primary, Sikic, Danijel, primary, Breyer, Johannes, primary, Bolenz, Christian, primary, Zengerling, Friedemann, primary, Erben, Philipp, primary, Schwamborn, Kristina, primary, Wirtz, Ralph M., primary, Horn, Thomas, primary, Nagy, Dora, primary, Toma, Marieta, primary, Kristiansen, Glen, primary, Büttner, Thomas, primary, Hahn, Oliver, primary, Grünwald, Viktor, primary, Darr, Christopher, primary, Erne, Eva, primary, Rausch, Steffen, primary, Bedke, Jens, primary, Schlack, Katrin, primary, Abbas, Mahmoud, primary, Zschäbitz, Stefanie, primary, Schwab, Constantin, primary, Mustea, Alexander, primary, Adam, Patrick, primary, Manseck, Andreas, primary, Wullich, Bernd, primary, Ritter, Manuel, primary, Hartmann, Arndt, primary, Gschwend, Jürgen, primary, Weichert, Wilko, primary, Erlmeier, Franziska, primary, Hölzel, Michael, primary, and Eckstein, Markus, primary

Published
2023
Full Text
View/download PDF

6. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Author

Klümper, Niklas, primary, Ralser, Damian J., additional, Ellinger, Jörg, additional, Roghmann, Florian, additional, Albrecht, Julia, additional, Below, Eduard, additional, Alajati, Abdullah, additional, Sikic, Danijel, additional, Breyer, Johannes, additional, Bolenz, Christian, additional, Zengerling, Friedemann, additional, Erben, Philipp, additional, Schwamborn, Kristina, additional, Wirtz, Ralph M., additional, Horn, Thomas, additional, Nagy, Dora, additional, Toma, Marieta, additional, Kristiansen, Glen, additional, Büttner, Thomas, additional, Hahn, Oliver, additional, Grünwald, Viktor, additional, Darr, Christopher, additional, Erne, Eva, additional, Rausch, Steffen, additional, Bedke, Jens, additional, Schlack, Katrin, additional, Abbas, Mahmoud, additional, Zschäbitz, Stefanie, additional, Schwab, Constantin, additional, Mustea, Alexander, additional, Adam, Patrick, additional, Manseck, Andreas, additional, Wullich, Bernd, additional, Ritter, Manuel, additional, Hartmann, Arndt, additional, Gschwend, Jürgen, additional, Weichert, Wilko, additional, Erlmeier, Franziska, additional, Hölzel, Michael, additional, and Eckstein, Markus, additional

Published
2022
Full Text
View/download PDF

10. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.

Author

Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, Bolenz C, Zengerling F, Erben P, Schwamborn K, Wirtz RM, Horn T, Nagy D, Toma M, Kristiansen G, Büttner T, Hahn O, Grünwald V, Darr C, Erne E, Rausch S, Bedke J, Schlack K, Abbas M, Zschäbitz S, Schwab C, Mustea A, Adam P, Manseck A, Wullich B, Ritter M, Hartmann A, Gschwend J, Weichert W, Erlmeier F, Hölzel M, and Eckstein M

Subjects
Humans, Nectins genetics, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, Cell Adhesion Molecules genetics, Cell Adhesion Molecules metabolism, Urinary Bladder Neoplasms pathology, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell genetics
Abstract

Purpose: The antibody-drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior assessment of the tumor receptor status as ubiquitous NECTIN-4 expression is assumed. Our objective was to determine the prevalence of membranous NECTIN-4 protein expression in primary tumors (PRIM) and patient-matched distant metastases (MET)., Experimental Design: Membranous NECTIN-4 protein expression was measured (H-score) by IHC in PRIM and corresponding MET (N = 137) and in a multicenter EV-treated cohort (N = 47). Progression-free survival (PFS) after initiation of EV treatment was assessed for the NECTIN-4-negative/weak (H-score 0-99) versus moderate/strong (H-score 100-300) subgroup. The specificity of the NECTIN-4 IHC staining protocol was validated by establishing CRISPR-Cas9-induced polyclonal NECTIN-4 knockouts., Results: In our cohort, membranous NECTIN-4 expression significantly decreased during metastatic spread (Wilcoxon matched pairs P < 0.001; median H-score = 40; interquartile range, 0-140), with 39.4% of MET lacking membranous NECTIN-4 expression. In our multicenter EV cohort, absence or weak membranous NECTIN-4 expression (34.0% of the cohort) was associated with a significantly shortened PFS on EV (log-rank P < 0.001)., Conclusions: Membranous NECTIN-4 expression is frequently decreased or absent in mUC tissue. Of note, the clinical benefit of EV strongly depends on membranous NECTIN-4 expression. Thus, our results are of highest clinical relevance and argue for a critical reconsideration of the current practice and suggest that the NECTIN-4 receptor status should be determined (ideally in a metastatic/progressive lesion) before initiation of EV. See related commentary by Aggen et al., p. 1377., (©2022 The Authors; Published by the American Association for Cancer Research.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results